Generated by AI
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment. The company develops multi-node therapies that target the PAM (PI3K/AKT/mTOR) signaling pathway, one of the most frequently altered oncogenic pathways in cancer, with the aim of blocking cancer growth signals while also managing the nutrient supply that fuels tumors. Its lead program, PIKTOR, is an all-oral investigational combination designed to achieve deeper pathway suppression with improved tolerability by inhibiting multiple nodes simultaneously. Faeth Therapeutics leverages a data-driven discovery platform that links tumor genotypes with specific therapeutic regimens and precision metabolic interventions, including nutrition-based strategies, to modulate cancer metabolism. Headquartered in San Francisco, California, and operating as a biotechnology research company, Faeth Therapeutics plays a specialized role in the oncology market by advancing metabolism-focused treatments for solid tumors within the broader biopharmaceutical and cancer therapeutics ecosystem.
Website1405 Research Boulevard
Rockville, MD, 20850
United States
The latest articles about SNSE.
Summary of May 15's posts. Generated by AI.
Summary of Feb 23's posts. Generated by AI.
No summary yet.
Summary of May 15's posts. Generated by AI.
Investors talking about SNSE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.